- Cat. No.
- A13826
PTC-209
PTC-209 is a novel potent and selective BMI-1 inhibitor, targeting the BMI-1 self-renewal machinery with an IC50 of ~0.5 μM.
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
BMI-1 inhibitors target a Polycomb group protein that silences genes and supports stem cell self-renewal. B cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) is a core subunit of Polycomb repressive complex 1 (PRC1). In 2004, PRC1 was shown to monoubiquitinate histone H2A, a mark linked to Polycomb silencing. A 2003 mouse study found BMI-1 to be required for maintaining adult self-renewing hematopoietic stem cells. PTC-209 lowers BMI-1 protein levels and was used in 2014 to study self-renewal of colorectal cancer-initiating cells. PTC-028 and unesbulin are two further compounds listed here as BMI-1 inhibitors. PRT 4165 instead inhibits the ubiquitin ligase activity of the complex of BMI-1 with its partner ring finger protein 1A (RING1A).
PTC-209 is a novel potent and selective BMI-1 inhibitor, targeting the BMI-1 self-renewal machinery with an IC50 of ~0.5 μM.
Synonyms: PTX209
PTC-209 HBr is the hydrobromide salt of PTC-209. PTC-209 is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM in HEK293T cell line, and results in irreversible reduction of cancer-initiating cells (CICs).
PRT 4165 is an inhibitor of Bmi1/Ring1A, subunits of the polycomb repressive complex 1 (PRC1). It prevents Bmi1/Ring1A-mediated ubiquitination and drug-induced degradation of topoisomerase 2alpha.
PTC-028 is an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification
Synonyms: PTC 596
PTC596 is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor.